Aquestive Therapeutics Inc. (AQST) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Aquestive Therapeutics In... (AQST)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

3.04

-0.07 (-2.25%)

At close: Jan 14, 2025, 3:59 PM

3.06

0.49%

After-hours Jan 14, 2025, 04:07 PM EST

undefined% (undefined)

Bid	3.02
Market Cap	277.64M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.46
PE Ratio (ttm)	-6.62
Forward PE	n/a
Analyst	Buy

Ask	3.06
Volume	1,019,935
Avg. Volume (20D)	1,596,690
Open	3.14
Previous Close	3.11
Day's Range	3.01 - 3.27
52-Week Range	2.24 - 6.23
Beta	undefined

About AQST

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral ...

[Show more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

IPO Date Jul 25, 2018

Employees 135

Stock Exchange NASDAQ

Ticker Symbol AQST

Website https://www.aquestive.com

Analyst Forecast

According to 8 analyst ratings, the average rating for AQST stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 195.57% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Aquestive Therapeutics Inc. is scheduled to release its earnings on Mar 4, 2025, during market hours.
Analysts project revenue of $13.13M, reflecting a -0.58% YoY shrinking and earnings per share of -0.13, making a 30.00% increase YoY.

Why Price Moved

3 weeks ago · Source

+5.2%

Aquestive Therapeutics shares are trading higher a... Unlock content with Pro Subscription

4 weeks ago · Source

+6.94%

Aquestive Therapeutics shares are trading higher after Cantor Fitzgerald initiated coverage on the stock with an Overweight rating and announced a price target of $17.

News

1 week ago · seekingalpha.com

Aquestive Therapeutics: Five Foci For 2025

Aquestive Therapeutics' Anaphylm is nearing FDA approval, potentially disrupting the U.S. anaphylaxis market dominated by EpiPen, with peak sales estimated at $300–400M. AQST-108, a topical epinephrin...

2 months ago · seekingalpha.com

Undercovered Dozen: Asbury Automotive, Globalstar, Northland Power, Aquestive Therapeutics +

The 'Undercovered' Dozen series highlights 12 lesser-covered stocks, offering fresh investment ideas and sparking community discussions on their potential. Xometry's AI-driven procurement software in ...

2 months ago · seekingalpha.com

Aquestive Therapeutics, Inc. (AQST) Q3 2024 Earnings Call Transcript

Aquestive Therapeutics, Inc. (NASDAQ:AQST ) Q3 2024 Earnings Call Transcript November 5, 2024 8:00 AM ET Company Participants Bennett Watson - IR, ICR Westwicke IR Dan Barber - CEO Ernie Toth - CFO Sh...

2 months ago · seekingalpha.com

Aquestive: Rare Opportunity With Dual Platform Strategy

Aquestive Therapeutics specializes in innovative film-based medicines and epinephrine products & delivery. The company's PharmFilm and Adrenaverse platforms offer unique competitive advantages, making...

2 months ago · zacks.com

Aquestive Therapeutics (AQST) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Although the revenue and EPS for Aquestive Therapeutics (AQST) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compar...

2 months ago · zacks.com

Aquestive Therapeutics (AQST) Reports Q3 Loss, Tops Revenue Estimates

Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.03 per share a year ago.